RIGEL PHARMACEUTICALS, INC. (RIGL) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.42B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-148.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-128.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $181.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $96.00K.
RIGEL PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $18.00K | $1.42B | $-148.00K | $-997.10M | $425.42M | 3 month · $6.90M | (m) | (m) |
| 2026-03-31 | (m) | $18.00K | $1.41B | $-128.00K | $-1.01B | $399.90M | 3 month · $3.49M | (m) | (m) |
| 2025-12-31 | $0.00 | $18.00K | $1.41B | $181.00K | $-1.02B | $391.48M | 12 month · $12.90M | (m) | (m) |
| 2025-09-30 | (m) | $18.00K | $1.41B | $96.00K | $-1.29B | $117.61M | 3 month · $3.41M | (m) | (m) |
| 2025-06-30 | (m) | $18.00K | $1.40B | $6.00K | $-1.32B | $81.93M | 3 month · $3.33M | (m) | (m) |
| 2025-03-31 | (m) | $18.00K | $1.40B | $-2.00K | $-1.38B | $18.57M | 3 month · $3.36M | (m) | (m) |
| 2024-12-31 | $0.00 | $18.00K | $1.39B | $10.00K | $-1.39B | $3.29M | 12 month · $12.48M | (m) | (m) |
| 2024-09-30 | (m) | $17.00K | $1.39B | $11.00K | $-1.40B | $-14.64M | 3 month · $2.68M | (m) | (m) |
| 2024-06-30 | (m) | $17.00K | $1.39B | $-9.00K | $-1.42B | $-29.91M | 3 month · $2.54M | (m) | (m) |
| 2024-03-31 | (m) | $175.00K | $1.38B | $-5.00K | $-1.42B | $-31.67M | 3 month · $5.14M | (m) | (m) |
| 2023-12-31 | (m) | $17.00K | $1.38B | $8.00K | $-1.41B | $-28.64M | 12 month · $8.85M | (m) | (m) |
| 2023-09-30 | (m) | $175.00K | $1.38B | $-15.00K | $-1.41B | $-31.83M | 3 month · $1.96M | (m) | (m) |
| 2023-06-30 | (m) | $175.00K | $1.37B | $-25.00K | $-1.40B | $-28.11M | 3 month · $2.19M | (m) | (m) |
| 2023-03-31 | (m) | $174.00K | $1.37B | $-27.00K | $-1.40B | $-24.26M | 3 month · $2.77M | (m) | (m) |
| 2022-12-31 | (m) | $174.00K | $1.37B | $-153.00K | $-1.38B | $-13.62M | 12 month · $12.51M | (m) | (m) |
| 2022-09-30 | (m) | $173.00K | $1.36B | $-286.00K | $-1.38B | $-19.83M | 3 month · $2.73M | (m) | (m) |
| 2022-06-30 | (m) | $173.00K | $1.36B | $-438.00K | $-1.36B | $-3.68M | 3 month · $2.44M | (m) | (m) |
| 2022-03-31 | (m) | $172.00K | $1.36B | $-416.00K | $-1.35B | $6.80M | 3 month · $3.24M | (m) | (m) |
| 2021-12-31 | (m) | $172.00K | $1.35B | $-102.00K | $-1.32B | $30.37M | 12 month · $9.59M | (m) | (m) |
| 2021-09-30 | (m) | $171.00K | $1.35B | $8.00K | $-1.30B | $49.67M | 3 month · $2.24M | (m) | (m) |
| 2021-06-30 | (m) | $171.00K | $1.35B | $7.00K | $-1.28B | $68.11M | 3 month · $2.31M | (m) | (m) |
| 2021-03-31 | (m) | $170.00K | $1.34B | $-1.00K | $-1.27B | $78.30M | 3 month · $2.67M | (m) | (m) |
| 2020-12-31 | (m) | $169.00K | $1.34B | $-4.00K | $-1.31B | $34.03M | 12 month · $7.39M | (m) | (m) |
| 2020-09-30 | (m) | $169.00K | $1.34B | $2.00K | $-1.29B | $50.95M | 3 month · $1.91M | (m) | (m) |
| 2020-06-30 | (m) | $169.00K | $1.34B | $46.00K | $-1.27B | $63.21M | 3 month · $1.78M | (m) | (m) |
| 2020-03-31 | (m) | $169.00K | $1.33B | $78.00K | $-1.25B | $78.50M | 3 month · $2.05M | (m) | (m) |
| 2019-12-31 | (m) | $168.00K | $1.33B | $23.00K | $-1.28B | $53.81M | 12 month · $9.21M | (m) | (m) |
| 2019-09-30 | (m) | $168.00K | $1.33B | $36.00K | $-1.26B | $68.91M | 3 month · $2.11M | (m) | (m) |
| 2019-06-30 | (m) | $168.00K | $1.33B | $43.00K | $-1.25B | $78.29M | 3 month · $2.69M | (m) | (m) |
| 2019-03-31 | (m) | $167.00K | $1.32B | $10.00K | $-1.23B | $95.31M | 3 month · $2.99M | (m) | (m) |
| 2018-12-31 | (m) | $167.00K | $1.32B | $-24.00K | $-1.21B | $109.88M | 12 month · $7.76M | (m) | (m) |
| 2018-09-30 | (m) | $166.00K | $1.32B | $-25.00K | $-1.21B | $103.47M | 3 month · $3.01M | (m) | (m) |
| 2018-06-30 | (m) | $166.00K | $1.31B | $-49.00K | $-1.19B | $123.57M | 3 month · $1.13M | (m) | (m) |
| 2018-03-31 | (m) | $148.00K | $1.24B | $-87.00K | $-1.16B | $79.81M | 3 month · $1.54M | (m) | (m) |
| 2017-12-31 | (m) | $147.00K | $1.24B | $-82.00K | $-1.14B | $100.65M | 12 month · $5.99M | (m) | (m) |
| 2017-09-30 | (m) | $125.00K | $1.17B | $-7.00K | $-1.11B | $56.17M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $124.00K | $1.16B | $-19.00K | $-1.10B | $69.61M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $123.00K | $1.16B | $-29.00K | $-1.08B | $84.08M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $100.00K | $1.12B | $-18.00K | $-1.06B | $55.03M | 12 month · $7.83M | (m) | (m) |
| 2016-09-30 | (m) | $99.00K | $1.11B | $9.00K | $-1.05B | $65.94M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $95.00K | $1.10B | $53.00K | $-1.02B | $73.72M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $91.00K | $1.08B | $49.00K | $-1.01B | $75.45M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $91.00K | $1.08B | $-44.00K | $-991.65M | $91.38M | 12 month · $7.40M | (m) | (m) |
| 2015-09-30 | (m) | $89.00K | $1.08B | $25.00K | $-978.96M | $96.41M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $88.00K | $1.07B | $11.00K | $-972.29M | $101.15M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $88.00K | $1.07B | $17.00K | $-958.38M | $112.15M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $88.00K | $1.07B | $-7.00K | $-940.18M | $128.25M | 12 month · $9.79M | (m) | (m) |
| 2014-09-30 | (m) | $88.00K | $1.06B | $16.00K | $-917.91M | $146.85M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $88.00K | $1.06B | $42.00K | $-896.97M | $165.73M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $88.00K | $1.06B | $38.00K | $-871.58M | $188.33M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $88.00K | $1.06B | $47.00K | $-849.27M | $208.25M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $87.00K | $1.06B | $129.00K | $-832.41M | $223.40M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $87.00K | $1.05B | $17.00K | $-808.59M | $245.05M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $87.00K | $1.05B | $78.00K | $-785.82M | $265.31M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $87.00K | $1.05B | $82.00K | $-760.25M | $289.10M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $72.00K | $909.40M | $106.00K | $-734.77M | $174.80M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $72.00K | $904.96M | $37.00K | $-709.32M | $195.75M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $71.00K | $901.07M | $25.00K | $-684.58M | $216.58M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $71.00K | $897.48M | $6.00K | $-661.41M | $236.15M | (m) | (m) | 12 month · $0.00 |
| 2011-09-30 | (m) | $71.00K | $893.53M | $-22.00K | $-635.62M | $257.96M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $71.00K | $890.24M | $60.00K | $-617.69M | (m) | (m) | $272.69M | (m) |
| 2010-12-31 | (m) | $52.00K | $741.55M | $-38.00K | $-575.43M | $166.13M | (m) | $166.13M | 12 month · $0.00 |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $109.87M | (m) | (m) | 12 month · $616.00K |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $104.17M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |